Literature DB >> 23912650

α-Synuclein overexpression represses 14-3-3θ transcription.

Huiping Ding1, Naomi S Fineberg, Michelle Gray, Talene A Yacoubian.   

Abstract

Previous gene microarray studies have shown that expression of 14-3-3θ is significantly decreased in an α-synuclein transgenic mouse model. In this study, we tested whether α-synuclein can regulate 14-3-3θ transcription. We demonstrate that the 14-3-3θ mRNA level is decreased in SH-SY5Y cells overexpressing α-synuclein. Luciferase activity under the control of the 14-3-3θ promoter is reduced both in stable SH-SY5Y cells constitutively overexpressing α-synuclein and in doxycycline-inducible SH-SY5Y cells upon α-synuclein induction, suggesting that the regulation of 14-3-3θ by α-synuclein occurs at the transcriptional level. Knockdown of α-synuclein by RNA interference does not increase the 14-3-3θ mRNA level. These findings suggest that α-synuclein represses 14-3-3θ transcription under pathologic conditions, but that regulation of 14-3-3θ expression is not a function of endogenous α-synuclein at baseline.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23912650      PMCID: PMC3809755          DOI: 10.1007/s12031-013-0086-5

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  42 in total

1.  Specification of 14-3-3 proteins in Lewy bodies.

Authors:  Daniela Berg; Olaf Riess; Antje Bornemann
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

2.  alpha-Synuclein locus triplication causes Parkinson's disease.

Authors:  A B Singleton; M Farrer; J Johnson; A Singleton; S Hague; J Kachergus; M Hulihan; T Peuralinna; A Dutra; R Nussbaum; S Lincoln; A Crawley; M Hanson; D Maraganore; C Adler; M R Cookson; M Muenter; M Baptista; D Miller; J Blancato; J Hardy; K Gwinn-Hardy
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

3.  Identification of novel isoform-selective inhibitors within class I histone deacetylases.

Authors:  Erding Hu; Edward Dul; Chiu-Mei Sung; Zunxuan Chen; Robert Kirkpatrick; Gui-Feng Zhang; Kyung Johanson; Ronggang Liu; Amparo Lago; Glenn Hofmann; Ricardo Macarron; Maite de los Frailes; Paloma Perez; John Krawiec; James Winkler; Michael Jaye
Journal:  J Pharmacol Exp Ther       Date:  2003-09-15       Impact factor: 4.030

4.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

5.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

6.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

7.  Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra.

Authors:  Renee M Miller; Linda M Callahan; Cindy Casaceli; Linlin Chen; Gretchen L Kiser; Buena Chui; Tamma M Kaysser-Kranich; Timothy J Sendera; Chockalingam Palaniappan; Howard J Federoff
Journal:  J Neurosci       Date:  2004-08-25       Impact factor: 6.167

8.  Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology.

Authors:  Filip Simunovic; Ming Yi; Yulei Wang; Laurel Macey; Lauren T Brown; Anna M Krichevsky; Susan L Andersen; Robert M Stephens; Francine M Benes; Kai C Sonntag
Journal:  Brain       Date:  2008-12-03       Impact factor: 13.501

9.  Global microRNA expression profiling of Caenorhabditis elegans Parkinson's disease models.

Authors:  Suvi Asikainen; Martina Rudgalvyte; Liisa Heikkinen; Kristiina Louhiranta; Merja Lakso; Garry Wong; Richard Nass
Journal:  J Mol Neurosci       Date:  2010-01-21       Impact factor: 3.444

10.  A cross-study transcriptional analysis of Parkinson's disease.

Authors:  Greg T Sutherland; Nicholas A Matigian; Alistair M Chalk; Matthew J Anderson; Peter A Silburn; Alan Mackay-Sim; Christine A Wells; George D Mellick
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

View more
  10 in total

1.  14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.

Authors:  H Ding; R Underwood; N Lavalley; T A Yacoubian
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

2.  14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.

Authors:  Bing Wang; Rachel Underwood; Anjali Kamath; Colleen Britain; Michael B McFerrin; Pamela J McLean; Laura A Volpicelli-Daley; Robert H Whitaker; William J Placzek; Katelyn Becker; Jiyan Ma; Talene A Yacoubian
Journal:  J Neurosci       Date:  2018-08-09       Impact factor: 6.167

3.  Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins.

Authors:  Sunny Rae Slone; Nicholas Lavalley; Michael McFerrin; Bing Wang; Talene Alene Yacoubian
Journal:  Neurobiol Dis       Date:  2015-04-08       Impact factor: 5.996

4.  14-3-3θ Does Not Protect against Behavioral or Pathological Deficits in Alzheimer's Disease Mouse Models.

Authors:  Mary Gannon; Bing Wang; Sara Anne Stringfellow; Stephan Quintin; Itzel Mendoza; Thanushri Srikantha; A Claire Roberts; Takashi Saito; Takaomi C Saido; Erik D Roberson; Talene A Yacoubian
Journal:  eNeuro       Date:  2022-06-24

5.  14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.

Authors:  Nicholas J Lavalley; Sunny R Slone; Huiping Ding; Andrew B West; Talene A Yacoubian
Journal:  Hum Mol Genet       Date:  2015-11-05       Impact factor: 6.150

6.  Complexin-1 and Foxp1 Expression Changes Are Novel Brain Effects of Alpha-Synuclein Pathology.

Authors:  Suzana Gispert; Alexander Kurz; Nadine Brehm; Katrin Rau; Michael Walter; Olaf Riess; Georg Auburger
Journal:  Mol Neurobiol       Date:  2014-08-12       Impact factor: 5.590

7.  Dysregulation of 14-3-3 proteins in neurodegenerative diseases with Lewy body or Alzheimer pathology.

Authors:  Michael B McFerrin; Xiaofei Chi; Gary Cutter; Talene A Yacoubian
Journal:  Ann Clin Transl Neurol       Date:  2017-06-07       Impact factor: 4.511

8.  14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.

Authors:  Rachel Underwood; Mary Gannon; Aneesh Pathak; Navya Kapa; Sidhanth Chandra; Alyssa Klop; Talene A Yacoubian
Journal:  Acta Neuropathol Commun       Date:  2021-01-07       Impact factor: 7.801

9.  Alpha-synucleinopathy reduces NMNAT3 protein levels and neurite formation that can be rescued by targeting the NAD+ pathway.

Authors:  Richard B Parsons; Altin Kocinaj; Gustavo Ruiz Pulido; Sarah A Prendergast; Anna E Parsons; Paul D Facey; Frank Hirth
Journal:  Hum Mol Genet       Date:  2022-08-25       Impact factor: 5.121

Review 10.  Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology.

Authors:  Francesca Longhena; Gaia Faustini; Maria Grazia Spillantini; Arianna Bellucci
Journal:  Int J Mol Sci       Date:  2019-01-02       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.